Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The consensus of evidence from angiographic trials demonstrates both coronary artery and clinical benefits from lowering of lipids by a variety of regimens. The findings of reduced arterial disease progression and increased regression have been convincing but, at best, modest in their magnitude. For example, among those treated intensively in FATS, the mean improvement in proximal stenosis severity per patient was < 1% stenosis, and only 12% of all lesions showed convincing regression. In view of these modest arterial benefits, the associated reductions in cardiovascular events have been surprisingly great. For example, coronary events were reduced 75% in FATS; this was entirely a result of a 93% reduction in the likelihood that a mildly or moderately diseased arterial segment would experience substantial progression to a severe lesion at the time of a clinical event. We believe that the magnitude of the clinical benefit is best explained in terms of this observation, according to the following lines of reasoning. Clinical events most commonly spring from lesions that are initially of mild or moderate severity and then abruptly undergo a disruptive transformation to a severe culprit lesion. The process of plaque fissuring, leading to plaque disruption and thrombosis, triggers most clinical coronary events. Fissuring is predicted by a large accumulation of core lipid in the plaque and by a high density of lipid-laden macrophages in its thinned fibrous cap. Lesions with these characteristics constitute only 10-20% of the overall lesion population but account for 80-90% of the acute clinical events. In the experimental setting, normalization of an atherogenic lipid profile substantially decreases the number of lipid-laden intimal macrophages (foam cells) and depletes cholesterol from the core lipid pool. In the clinical setting, intensive lipid lowering virtually halts the progression of mild and moderate lesions to clinical events. Thus, the reduction in clinical events observed in these trials appears to be best explained by the relation of the lipid and foam cell content of the plaque to its likelihood of fissuring and by the effects of lipid-lowering therapy on these "high-risk" features of plaque morphology. The composite of data presented here supports the hypothesis that lipid-lowering therapy selectively depletes (regresses) that relatively small but dangerous subgroup of fatty lesions containing a large lipid core and dense clusters of intimal macrophages. By doing so, these lesions are effectively stabilized and clinical event rate is accordingly decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide: physiology, pathophysiology, and pharmacology.
Moncada, S., Palmer, R. M., & Higgs, E. A. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06663-3 · Cited by 15,525
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Epstein, F. H., Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,427
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
Compensatory Enlargement of Human Atherosclerotic Coronary Arteries
Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R., & Kolettis, G. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162204 · Cited by 3,623
Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary Arteries
Ludmer, P. L., Selwyn, A. P., Shook, T. L., Wayne, R. R., Mudge, G. H., Alexander, R. W., & Ganz, P. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610233151702 · Cited by 2,425
Can lifestyle changes reverse coronary heart disease?
Ornish, D., Brown, S. E., Billings, J. H., Scherwitz, L. W., Armstrong, W. T., Ports, T. A., McLanahan, S. M., Kirkeeide, R. L., Gould, K. L., & Brand, R. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91656-u · Cited by 2,338
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Self-citationEndothelium‐derived relaxing and contracting factors
Furchgott, R. F., & Vanhoutte, P. M. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.9.2545495 · Cited by 1,993
Cited by
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., & Lerman, A. (2000) · Circulation · doi:10.1161/01.cir.101.9.948 · Cited by 2,043
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,028
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Self-citationUpregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors
Laufs, U., La Fata, V., Plutzky, J., & Liao, J. K. (1998) · Circulation · doi:10.1161/01.cir.97.12.1129 · Cited by 1,839
Coronary Risk Factors and Plaque Morphology in Men with Coronary Disease Who Died Suddenly
Burke, A. P., Farb, A., Malcom, G. T., Liang, Y.-H., Smialek, J., & Virmani, R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705013361802 · Cited by 1,745
Pathogenesis of atherosclerosis
Falk, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.068 · Cited by 1,447
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P., & Ganz, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320802 · Cited by 1,109
Topol, E. J., & Nissen, S. E. (1995) · Circulation · doi:10.1161/01.cir.92.8.2333 · Cited by 1,103
Wexler, L., Brundage, B., Crouse, J., Detrano, R., Fuster, V., Maddahi, J., Rumberger, J., Stanford, W., White, R., & Taubert, K. (1996) · Circulation · doi:10.1161/01.cir.94.5.1175 · Cited by 1,070
INFLAMMATION AND ATHEROSCLEROSIS
Hansson, G. K., Robertson, A.-K. L., & Söderberg-Nauclér, C. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100100 · Cited by 1,046
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.9.1512 · Cited by 965
Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
O'Driscoll, G., Green, D., & Taylor, R. R. (1997) · Circulation · doi:10.1161/01.cir.95.5.1126 · Cited by 952
Types of Dietary Fat and Risk of Coronary Heart Disease: A Critical Review
Hu, F. B., Manson, J. E., & Willett, W. C. (2001) · Journal of the American College of Nutrition · doi:10.1080/07315724.2001.10719008 · Cited by 902
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 867
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Statins do more than just lower cholesterol
Vaughan, C. J., Murphy, M. B., & Buckley, B. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05190-2 · Cited by 698
Rubinshtein, R., Kuvin, J. T., Soffler, M., Lennon, R. J., Lavi, S., Nelson, R. E., Pumper, G. M., Lerman, L. O., & Lerman, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq010 · Cited by 683
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Egashira, K., Hirooka, Y., Kai, H., Sugimachi, M., Suzuki, S., Inou, T., & Takeshita, A. (1994) · Circulation · doi:10.1161/01.cir.89.6.2519 · Cited by 597
Aikawa, M., Rabkin, E., Sugiyama, S., Voglic, S. J., Fukumoto, Y., Furukawa, Y., Shiomi, M., Schoen, F. J., & Libby, P. (2001) · Circulation · doi:10.1161/01.cir.103.2.276 · Cited by 588
Stabilization of atherosclerotic plaques: New mechanisms and clinical targets
Libby, P., & Aikawa, M. (2002) · Nature Medicine · doi:10.1038/nm1102-1257 · Cited by 580
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice
Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., et al. (2002) · Circulation · doi:10.1161/01.cir.0000039325.03698.36 · Cited by 563
Aikawa, M., Rabkin, E., Okada, Y., Voglic, S. J., Clinton, S. K., Brinckerhoff, C. E., Sukhova, G. K., & Libby, P. (1998) · Circulation · doi:10.1161/01.cir.97.24.2433 · Cited by 555
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 479
Corti, R., Fayad, Z. A., Fuster, V., Worthley, S. G., Helft, G., Chesebro, J., Mercuri, M., & Badimon, J. J. (2001) · Circulation · doi:10.1161/01.cir.104.3.249 · Cited by 478
Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier
Muller, J. E., Abela, G. S., Nesto, R. W., & Tofler, G. H. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90772-2 · Cited by 459
Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease
Patrono, C., & FitzGerald, G. A. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2309 · Cited by 453
Lacoste, L., Lam, J. Y. T., Hung, J., Letchacovski, G., Solymoss, C. B., & Waters, D. (1995) · Circulation · doi:10.1161/01.cir.92.11.3172 · Cited by 441
Ericsson, C.-G., de Faire, U., Grip, L., Svane, B., Hamsten, A., & Nilsson, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91343-4 · Cited by 426
Mechanical Principles in Arterial Disease
O’Rourke, M. (1995) · Hypertension · doi:10.1161/01.hyp.26.1.2 · Cited by 401
Fukumoto, Y., Libby, P., Rabkin, E., Hill, C. C., Enomoto, M., Hirouchi, Y., Shiomi, M., & Aikawa, M. (2001) · Circulation · doi:10.1161/01.cir.103.7.993 · Cited by 384
Niebauer, J., Hambrecht, R., Velich, T., Hauer, K., Marburger, C., Kälberer, B., Weiss, C., von Hodenberg, E., Schlierf, G., Schuler, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.8.2534 · Cited by 372
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 367
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
In Vivo Formation of 8-Epi-Prostaglandin F2αIs Increased in Hypercholesterolemia
Davi, G., Alessandrini, P., Mezzetti, A., Minotti, G., Bucciarelli, T., Costantini, F., Cipollone, F., Bon, G. B., Ciabattoni, G., & Patrono, C. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.3230 · Cited by 350
Kawasaki, M., Takatsu, H., Noda, T., Sano, K., Ito, Y., Hayakawa, K., Tsuchiya, K., Arai, M., Nishigaki, K., Takemura, G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000017200.47342.10 · Cited by 336
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 333
Gould, K. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530110056036 · Cited by 329
Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L. C., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
Meek, R. L., Urieli-Shoval, S., & Benditt, E. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3186 · Cited by 298
Baumgart, D., Schmermund, A., Goerge, G., Haude, M., Ge, J., Adamzik, M., Sehnert, C., Altmaier, K., Groenemeyer, D., Seibel, R., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00147-2 · Cited by 295
Range of serum cholesterol values in the population developing coronary artery disease
Kannel, W. B. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80474-3 · Cited by 289
Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty
Weintraub, W. S., Boccuzzi, S. J., Klein, J. L., Kosinski, A. S., King, S. B., Ivanhoe, R., Cedarholm, J. C., Stillabower, M. E., Talley, J. D., DeMaio, S. J., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312002 · Cited by 289
Zhao, X.-Q., Yuan, C., Hatsukami, T. S., Frechette, E. H., Kang, X.-J., Maravilla, K. R., & Brown, B. G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.098463 · Cited by 284
Self-citationKroon, A. A., Aengevaeren, W. R. M., van der Werf, T., Uijen, G. J. H., Reiber, J. H. C., Bruschke, A. V. G., & Stalenhoef, A. F. H. (1996) · Circulation · doi:10.1161/01.cir.93.10.1826 · Cited by 275
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Ahmed, I., Lakhani, M. S., Gillett, M., John, A., & Raza, H. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00224-2 · Cited by 267
Stoudt, G., Bamberger, M., Warner, G. J., Johnson, W. J., & Rothblat, G. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5772 · Cited by 261
Increased winter mortality from acute myocardial infarction and stroke: the effect of age
Sheth, T., Nair, C., Muller, J., & Yusuf, S. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00137-0 · Cited by 259
The lipid and non-lipid effects of statins
Wierzbicki, A. S., Poston, R., & Ferro, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00055-x · Cited by 253
Walldius, G., Erikson, U., Olsson, A. G., Bergstrand, L., Hådell, K., Johansson, J., Kaijser, L., Lassvik, C., Mölgaard, J., Nilsson, S., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90579-7 · Cited by 248
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
“Retardation of the progression of coronary (11) and femoral (12) atherosclerosis has been related to a decrease of LDL cholesterol and an increase of high-density lipoprotein (HDL) cholesterol levels, in agreement with the general concept of the role of HDL in reverse cholesterol transport (13).”
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Approach to lipoprotein management in 2001 National Cholesterol Guidelines
Grundy, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02631-0 · Cited by 128
Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
Fujino, H., Saito, T., Tsunenari, Y., Kojima, J., & Sakaeda, T. (2004) · Xenobiotica · doi:10.1080/00498250400015319 · Cited by 98
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease
Reiss, A. B., Siller, K. A., Rahman, M. M., Chan, E. S. L., Ghiso, J., & de Leon, M. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.009 · Cited by 73
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
Crouse, J. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600012-jlr200 · Cited by 66
Medical Treatment of Peripheral Artery Disease
Gornik, H. L., & Creager, M. A. (2013) · Vascular Medicine: A Companion to Braunwald's Heart Disease · doi:10.1016/b978-1-4377-2930-6.00019-7 · Cited by 12
Metadata
- Authors
- Brown, B. G., Zhao, X. Q., Sacco, D. E., & Albers, J. J.
- Venue
- Circulation
- Published
- 1993-06
- Volume
- 87
- Issue
- 6
- Pages
- 1781-1791
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2089900480
- Cited by
- 821
- References
- 57
- FWCI
- 60.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.